BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22994923)

  • 1. Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study.
    Heemann U; Kliem V; Budde K; Hamza A; Jürgensen JS; Juarez F; Arns W; Rath T; Haller H
    Clin Transplant; 2012; 26(6):919-26. PubMed ID: 22994923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
    Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
    Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
    Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.
    Krischock L; Gullett A; Bockenhauer D; Rees L; Trompeter RS; Marks SD
    Pediatr Transplant; 2009 Jun; 13(4):475-81. PubMed ID: 18992054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
    Tsai MK; Lee CY; Hu RH; Lee PH
    J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study.
    Narayanan M; Pankewycz O; Shihab F; Wiland A; McCague K; Chan L
    Clin Transplant; 2014 Feb; 28(2):184-91. PubMed ID: 24372743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: the TranCept Switch study.
    Meier-Kriesche HU; Merville P; Tedesco-Silva H; Heemann U; Kes P; Haller H; Rostaing L; Gafner N; Bernasconi C
    Transplantation; 2011 May; 91(9):984-90. PubMed ID: 21464796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
    Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
    Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial.
    Höcker B; van Gelder T; Martin-Govantes J; Machado P; Tedesco H; Rubik J; Dehennault M; Garcia Meseguer C; Tönshoff B;
    Nephrol Dial Transplant; 2011 Mar; 26(3):1073-9. PubMed ID: 20670958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
    Remuzzi G; Cravedi P; Costantini M; Lesti M; Ganeva M; Gherardi G; Ene-Iordache B; Gotti E; Donati D; Salvadori M; Sandrini S; Segoloni G; Federico S; Rigotti P; Sparacino V; Ruggenenti P
    J Am Soc Nephrol; 2007 Jun; 18(6):1973-85. PubMed ID: 17460145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
    Vasquez EM; Sifontis NM; Pollak R; Benedetti E
    Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.